Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities.
Human immunodeficiency virus (HIV) protease inhibitors are associated with several metabolic abnormalities including hypercholesterolemia and hypertriglyceridemia. Fenofibrate is a new lipid-lowering agent for adults with very high triglyceride levels that was administered to two HIV-positive patients who were taking protease inhibitors and developed hypertriglyceridemia. Starting dosages were 134 and 201 mg/day, and were increased to 268 mg/day in both patients. Triglyceride levels decreased from 1450 to 337 mg/dl (76.8%) and from 1985 to 322 mg/dl (83.8%), respectively, after 10 months of therapy. High-density lipoprotein levels increased in both patients.
Thomas
J C
JC
Department of Medicine, Medical University of South Carolina, Charleston 29403, USA.
Lopes-Virella
M F
MF
Del Bene
V E
VE
Cerveny
J D
JD
Taylor
K B
KB
McWhorter
L S
LS
Bultemeier
N C
NC
D000328:Adult; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000502:physiology
D017320:HIV Protease Inhibitors; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D011345:Fenofibrate